Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions.

AIDS (London, England) - 12 Apr 2002

Martinez-Picado Javier, Morales-Lopetegi Kristina, Wrin Terri, Prado Julia G, Frost Simon D W, Petropoulos Christos J, Clotet Bonaventura, Ruiz Lidia

Abstract excerpt

BACKGROUND: A new HIV-1 treatment strategy based on repeated structured treatment interruptions (STI) is currently being evaluated in clinical trials to determine whether immune cell-mediated control of viral replication can be stimulated by intermittent periods of viral replication. The potential for selection of drug-resistant quasi-species remains a major concern of such a treatment strategy. METHODS: Plasma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Drug Resistance, Microbial

Share to HIV Infections

Share to RNA, Viral

Share to Viral Load

Source

Identifiers

PMID: 11919491
DOI: 10.1097/00002030-200204120-00009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions.PMID 11919491Read ↗

Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection.Semantic proximity Read ↗

Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.Semantic proximity Read ↗

Drug resistance mutations during structured treatment interruptions.Semantic proximity Read ↗

Emergence of Minor Populations of Human Immunodeficiency Virus Type 1 Carrying the M184V and L90M Mutations in Subjects Undergoing Structured Treatment InterruptionsSemantic proximity Read ↗

Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.Semantic proximity Read ↗

Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1?Semantic proximity Read ↗

Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients.Semantic proximity Read ↗

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.Semantic proximity Read ↗

Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions.Semantic proximity Read ↗

Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response.Semantic proximity Read ↗

Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus.Semantic proximity Read ↗

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.